Press release
Personal Care
October 28, 2013

Evonik achieves cosmetic GMP (ISO 22716) confirmation for North American sites

With the confirmation of another three facilities in Hopewell, Janesville and Mapleton Evonik raises the number of cosmetic GMP certified production sites to ten. ISO 22716 refers to the manufacturing process of cosmetics as well as raw materials. It includes guidelines for quality-related aspects of a product.
This confirmation guarantees that Evonik focuses on the appropriate principles and methods during production, controlling, storage and distribution. In addition to the European facilities, which received accreditation in 2012, also the production sites in NAFTA fulfill the guidelines of GMP now.

"The acknowledgement for our American and European production sites shows that we are able to fulfill the high demands of our customers in the cosmetic industry concerning the product quality during production and storage. Therefore, we can raise the customer satisfaction.

Due to the fact that we are aiming to realize these quality demands globally we are planning a promptly inclusion of our Asian sites for this standard", outlines Klaus Nawroth, Quality Management and Compliance Evonik Personal Care.

Thus, customers of Evonik can rely on the standard of GMP during the whole manufacturing process.

Please find corresponding certificates and further information on our Personal Care website: www.evonik.com/personal-care

Company information

Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.4 billion and an operating profit (adjusted EBITDA) of about €2.4 billion (excluding Real Estate in both cases).

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.